Codiak

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide range of diseases with unmet medical needs. By harnessing the biology of exosomes as a natural intercellular transfer mechanism, Codiak has developed its proprietary engEx platform to expand on the innate properties of exosomes to design and engineer novel exosome therapeutic candidates. Leveraging its engEx platform, Codiak has generated a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disorders, and infectious diseases.